RPT 2950
Alternative Names: RPT-2950Latest Information Update: 14 Sep 2023
At a glance
- Originator ROME Therapeutics
- Class Antineoplastics
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders